Business
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needsCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the
About this update from Intellia Therapeutics, Inc.
[{"type":"image","alt":"Intellia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Intellia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DZg.lk3JYo_QYqp_MgL6yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d","width":300,"height":150}},"lazy":false},{"type":"text","content":"Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs","length":202,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) that took place this past weekend in Philadelphia, Pennsylvania. All posters are available on intelliatx.com on the Scientific Publications & Presentations page.","length":550,"tagName":"p"},{"type":"text","content":"Poster Presentation Details: ","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Long-Term Durability and Safety of Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002) 50 mg in Patients with Hereditary AngioedemaSession: Allergic Skin DiseasesPoster Number: 061Presenter: Markus Magerl, M.D, Professor, Head of Clinical Trials, Charité - Universitätsmedizin Berlin Institute of Allergology","length":309,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In this pooled Phase 1/2 analysis (n=32), a one-time 50 mg dose of lonvo-z led to deep, stable and durable reductions in plasma kallikrein across all patients with up to three years of follow-up.","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Across the 32 patients, the mean monthly attack rate was consistently ≤0.2, representing a mean reduction of 96% in HAE attacks from baseline through last follow-up. Of the 32 patients, 31 ...